BLAINJECTIONINJECTABLE
Approved
Nov 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ZIEXTENZO (pegfilgrastim-bmez) by Novartis. Approved for leukocyte growth factor [epc]. First approved in 2019.
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZIEXTENZO is a pegfilgrastim biosimilar (pegfilgrastim-bmez) developed by Novartis, approved in 2019 as a cytokine therapeutic. It functions as a leukocyte growth factor to stimulate neutrophil production in cancer patients undergoing chemotherapy. The product is indicated for reducing the duration of chemotherapy-induced neutropenia and associated complications.
$10MPart D
PeakStable
Product is at peak commercial stage with modest Part D spending ($10M), indicating established market presence but constrained growth potential in a mature biosimilar category.
Mechanism of Action
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ZIEXTENZO offers 6 linked career opportunities primarily in R&D and Legal functions, reflecting post-approval support, regulatory compliance, and potential line-extension work. Roles skew technical (analytical, ADME) rather than commercial, suggesting limited field-based growth but stable backend manufacturing and quality roles.
Scientist IIScientist
Worked on ZIEXTENZO at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.